Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 195

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 195
---
 to the 2024 Loan Agreement to extend the maturity date until the earlier
of August 31, 2025, or the consummation of an IPO.

<div align='center'>114</div>

On December 1, 2024, we entered
into a loan agreement with our Chief Executive Officer, or the December 2024 Loan Agreement, according to which accrued payroll salary
owed to him in the aggregate amount of $117,000 plus VAT was converted into a loan. The loan amount bears interest at an 8% annual rate,
and is due upon the earlier of the consummation of this offering or March 31, 2025. In addition, upon maturity, the Company will pay to
our Chief Executive Officer an aggregate risk premium equal to 30% of the loan amount (or approximately $35,100). If a registration statement
for an initial public offering is made effective no later than March 31, 2025, then the maturity date will be extended to June 30, 2025.
In addition, pursuant to the December 2024 Loan Agreement, upon the consummation of this offering the Company will issue warrants, or
the CEO Loan Warrants, exercisable for a period of three years from the date of the issuance, to purchase such number of Ordinary Shares
equal to two times the respective loan amount divided by 75% of the lowest price per Ordinary Share during the first five trading days
following the consummation of this offering, at an exercise price equal to 75% of the lowest price per Ordinary Share during the first
five trading days following the consummation of this offering. The outstanding debt will become immediately due and payable upon an event
of default (as defined in the December 2024 Loan Agreement), which shall be deemed to have occurred upon certain circumstances as detailed
in the December 2024 Loan Agreement. On March 31, 2025, we and our Chief Executive Officer entered an amendment to the December 2024 Loan
Agreement to extend the maturity date until the earlier of August 31, 2025, or the consummation of an IPO.

In April 2025, we
entered into bridge loan agreements, or the 2025 Loan Agreements, pursuant to which we obtained bridge loans in the aggregate
amount of $110,000 from certain lenders, including Dr. Ehud Geller, the chairman and a member of the board of directors, and Pini
Ben El